• Earlier this year, Viking Therapeutics began a Phase 1 single ascending dose trial of VK3019, a dual amylin and calcitonin receptor agonist being tested as a potential obesity treatment in adults with excess weight.
• This first-in-human study expands Viking’s obesity pipeline beyond its GLP‑1/GIP program, highlighting a multi-mechanism approach that could broaden its future treatment profile if development progresses successfully.
• We’ll now examine how adding VK3019 as an early-stage obesity candidate could influence Viking Therapeutics’ broader investment narrative and risk profile.

The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Viking Therapeutics Investment Narrative Recap

To own Viking Therapeutics today, you need to believe its obesity franchise, led by VK2735, can eventually turn large R&D losses into meaningful revenue despite intense competition and zero current sales. The launch of VK3019 broadens the story beyond a single mechanism, but this Phase 1 trial does not change the near term focus on VANQUISH Phase 3 readouts as the key catalyst or the company’s heavy cash burn as the main risk.

The VK3019 first in human trial fits beside Viking’s existing programs, but the most relevant recent update is the progress around VK2735, including VANQUISH-2 enrollment and oral Phase 3 planning. Those late stage obesity programs, supported by ECO data showing double digit weight loss with oral VK2735, remain central to whether current valuation, recent share price strength and optimistic analyst targets can be justified over time.

Yet while VK3019 adds a new angle, investors should also be aware of the risk that continued high R&D spending without near term revenue could...

Viking Therapeutics' narrative projects $118.5 million revenue and $12.9 million earnings by 2029. This requires an earnings increase of about $372.5 million from -$359.6 million today.

Uncover how Viking Therapeutics' forecasts yield a $92.72 fair value, a 132% upside to its current price.

Exploring Other Perspectives

Compared with consensus, the most optimistic analysts were modeling about US$497.5 million of revenue and US$62.2 million of earnings by 2029, so VK3019’s launch may either reinforce that bullish view or prompt you to reconsider how concentrated those expectations still are in VK2735’s success.

Explore 12 other fair value estimates on Viking Therapeutics - why the stock might be worth over 2x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Viking Therapeutics research is our analysis highlighting 2 important warning signs that could impact your investment decision.
• Our free Viking Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Viking Therapeutics' overall financial health at a glance.

Ready For A Different Approach?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
• Find 44 companies with promising cash flow potential yet trading below their fair value.
• Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.